The level of thyroid-stimulating immunoglobulin that predicts whether Graves' disease will return after treatment is lower than the level used to diagnose the disease initially.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A meta-analysis could determine whether the predictive cutoff (66.5%) is consistently lower than diagnostic cutoffs across different assays and populations.
Systematic review and meta-analysis of all studies reporting TSI bioassay cutoffs for both diagnosis and relapse prediction in Graves' disease, comparing mean cutoffs, confidence intervals, and assay methods.
An RCT could test whether using a lower cutoff (66.5%) for drug withdrawal reduces relapse compared to using the diagnostic cutoff (140%).
Multicenter RCT of 400 adults with Graves' disease, randomized to withdraw ATD when TSI <140% vs. TSI <66.5%. Primary outcome: relapse rate at 2 years.
A prospective cohort could confirm that patients with TSI between 66.5% and 140% are at intermediate relapse risk, validating the distinction between diagnostic and prognostic thresholds.
Prospective cohort of 500 adults with Graves' disease, with TSI measured at diagnosis and at ATD discontinuation. Patients grouped by TSI at discontinuation: <66.5%, 66.5–140%, >140%. Primary outcome: relapse at 2 years.
A case-control study could compare TSI dynamics between patients who relapsed with TSI <140% vs. those who did not, to explore why the diagnostic threshold is insufficient for prognosis.
Case-control study of 100 patients who relapsed with TSI <140% at discontinuation and 100 who did not, comparing TSI trajectories from diagnosis to discontinuation.
A cross-sectional study could compare TSI levels at diagnosis versus discontinuation in the same patients to assess whether the predictive cutoff reflects disease evolution.
Cross-sectional analysis of paired TSI measurements at diagnosis and ATD discontinuation in 200 adults with Graves' disease, comparing mean values and correlation between time points.